Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know

Core Viewpoint - Aldeyra Therapeutics, Inc. (ALDX) shows significant potential for upside, with a mean price target of $9 indicating a 65.8% increase from the current trading price of $5.43, which has already gained 28.1% over the past four weeks [1]. Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.22, where the lowest estimate is $7.00 (28.9% increase) and the highest is $10.00 (84.2% increase) [2]. - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, indicating a potential starting point for further research [9]. Earnings Estimates and Analyst Agreement - There is increasing optimism among analysts about ALDX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with near-term stock price movements [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 19.4%, with one estimate moving higher and no negative revisions [12]. Zacks Rank and Investment Potential - ALDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]. - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a good guide for potential investment [14].